Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.

Autor: Witjes VM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Hermkens DMA; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Swillens JEM; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.; IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands., Smolders YHCM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Mourits MJE; Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Ausems MGEM; Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., de Hullu JA; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands., Ligtenberg MJL; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Hoogerbrugge N; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. Nicoline.Hoogerbrugge@radboudumc.nl.; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Nicoline.Hoogerbrugge@radboudumc.nl.

Publikováno v: Familial cancer [Fam Cancer] 2024 Nov; Vol. 23 (4), pp. 429-436. Date of Electronic Publication: 2024 May 29.

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.

Autor: Stroot IAS; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands. Electronic address: i.a.s.stroot@umcg.nl., Bart J; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Hollema H; University of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, the Netherlands., Jalving M; University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands., Wagner MM; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., Yigit R; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands., van Doorn HC; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Gynecologic Oncology, Rotterdam, the Netherlands., de Hullu JA; Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Gaarenstroom KN; Leiden University Medical Center, Department of Obstetrics and Gynecology, Leiden, the Netherlands., van Beurden M; Antoni van Leeuwenhoek, Department of Gynecology, Amsterdam, the Netherlands., van Lonkhuijzen LRCW; Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Department of Gynecologic Oncology, Amsterdam, the Netherlands., Slangen BFM; Maastricht University Medical Center, Department of Gynecology, Maastricht, the Netherlands., Zweemer RP; University Medical Center Utrecht, Department of Gynecologic Oncology, Utrecht, the Netherlands., Gómez García EB; University Medical Center Maastricht, Department of Clinical Genetics, Maastricht, the Netherlands., Ausems MGEM; University Medical Center Utrecht, Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, Utrecht, the Netherlands., Boere IA; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Medical Oncology, Rotterdam, the Netherlands., van Hest LP; Amsterdam UMC, Location Vrije Universiteit Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., Duijkers FAM; Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam, the Netherlands., van Asperen CJ; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Schmidt MK; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands; Netherlands Cancer Institute, Department of Epidemiology, Amsterdam, the Netherlands; Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, the Netherlands., Wevers MR; Radboud University Medical Center, Department of Clinical Genetics, Nijmegen, the Netherlands., Ruijs MWG; Netherlands Cancer Institute, Department of Clinical Genetics, Amsterdam, the Netherlands., Devilee P; Leiden University Medical Center, Department of Human Genetics & Department of Pathology, Leiden, the Netherlands., Collée JM; Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Clinical Genetics, Rotterdam, the Netherlands., Hebon Investigators; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, the Netherlands., de Bock GH; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands., Mourits MJE; University of Groningen, University Medical Center Groningen, Department of Gynecologic Oncology, Groningen, the Netherlands.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Aug; Vol. 187, pp. 198-203. Date of Electronic Publication: 2024 May 24.

Increased Interferon Signaling in Vaginal Tissue of Patients With Primary Sjögren Syndrome.

Autor: Visser A; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands., van Nimwegen JF; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands., Wilbrink R; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands., Liefers SC; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands., van der Tuuk K; K. van der Tuuk, MD, PhD, M.J.E. Mourits, MD, PhD, University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynaecology, Groningen, the Netherlands., Mourits MJE; K. van der Tuuk, MD, PhD, M.J.E. Mourits, MD, PhD, University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynaecology, Groningen, the Netherlands., Diercks GFH; G.F.H. Diercks, MD, PhD, J. Bart, MD, PhD, B. van der Vegt, MD, PhD, University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands., Bart J; G.F.H. Diercks, MD, PhD, J. Bart, MD, PhD, B. van der Vegt, MD, PhD, University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands., van der Vegt B; G.F.H. Diercks, MD, PhD, J. Bart, MD, PhD, B. van der Vegt, MD, PhD, University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands., van Kempen LC; L.C. van Kempen, MD, PhD, University of Antwerp, Antwerp University Hospital, Department of Pathology, Antwerp, Belgium., Bootsma H; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands., Kroese FGM; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands., Verstappen GM; A. Visser, BSc, J.F. van Nimwegen, MD, PhD, R. Wilbrink, MD, S.C. Liefers, PhD, H. Bootsma, MD, PhD, F.G.M. Kroese, PhD, G.M. Verstappen, PharmD, PhD, University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, the Netherlands; G.M.P.J.Verstappen@umcg.nl.

Publikováno v: The Journal of rheumatology [J Rheumatol] 2024 Jul 01; Vol. 51 (7), pp. 687-695. Date of Electronic Publication: 2024 Jul 01.

BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study.

Autor: Lanjouw L; Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., Bart J; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., Mourits MJE; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., Willems SM; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., van der Hout AH; Department of Genetics, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., Ter Elst A; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., de Bock GH; Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.

Publikováno v: Cancers [Cancers (Basel)] 2024 Apr 26; Vol. 16 (9). Date of Electronic Publication: 2024 Apr 26.

[Gender pay gap in a large university hospital in the Netherlands].

Autor: Mourits MJE; UMC Groningen-Universiteit van Groningen, afd. Obstetrie en Gynaecologie,Groningen.; Contact: m.j.e.mourits@umcg.nl., Schröder CP; UMC Groningen-Universiteit van Groningen, afd. Medische Oncologie, Groningen.

Publikováno v: Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2024 Mar 04; Vol. 168. Date of Electronic Publication: 2024 Mar 04.